Structure, function, and nutrition of lactoferrin

Mineral Containing Proteins: Roles in Nutrition

Volumn , Issue , 2017, Pages 33-61

  Du, Ming ^a   Liu, Meng ^b   Fan, Fengjiao ^b   Shi, Pujie ^b   Tu, Maolin ^b  

^a DALIAN POLYTECHNIC UNIVERSITY   (China)

^b HARBIN INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Bioactivity; Function; Lactoferrin; Mechanism; Structure

Indexed keywords

EID: 85030657681     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-981-10-3596-8_2     Document Type: Chapter

References (164)

1. Baker EN, Baker HM. A structural framework for understanding the multifunctional character of lactoferrin. Biochimie. 2009;91:3-10.
2. García-Montoya IA, Cendón TS, Arévalo-Gallegos S, Rascón-Cruz Q. Lactoferrin a multiple bioactive protein: an overview. Biochim Biophys Acta. 2012;1820:226-36.
3. Nuijens JH, van Berkel PH, Schanbacher FL. Structure and biological actions of lactoferrin. J Mammary Gland Biol Neoplasia. 1996;1:285-95.
4. Reiter B, Brock J, Steel ED. Inhibition of Escherichia coli by bovine colostrum and post-colostral milk. II. The bacteriostatic effect of lactoferrin on a serum susceptible and serum resistant strain of E. coli. Immunology. 1975;28:71-82.
5. Ellison RD, Giehl TJ, LaForce FM. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun. 1988;56:2774-81.
6. Ellison R. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Investig. 1991;88:1080-171.
7. Van Veen HA, Geerts ME, van Berkel PH, Nuijens JH. The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis. Eur J Biochem. 2004;271:678-84.
8. Cornish J, Palmano K, Callon KE, Watson M, Lin JM, Valenti P, Naot D, Grey AB, Reid IR. Lactoferrin and bone; structure-activity relationships. Biochem Cell Biol. 2006;84:297-302.
9. Cornish J, Callon KE, Naot D, Palmano KP, Banovic T, Bava U, Watson M, Lin JM, Tong PC, Qi C, Chan VA, Reid HE, Fazzalari N, Baker HM, Baker EN, Haggarty NW, Grey AB, Reid IR. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology. 2004;145:4366-74.
10. Masson P, Heremans J. Lactoferrin in milk from different species. Comp Biochem Physiol B. 1971;39:119-IN113.
11. Sanchez L, Aranda P, Pérez M, Calvo M. Concentration of lactoferrin and transferrin throughout lactation in cow's colostrum and milk. Biol Chem Hoppe Seyler. 1988;369:1005-8.
12. Baker E. Structure and reactivity of transferrins. Adv Inorg Chem. 1994;41:389-463.
13. Sreedhara A, Flengsrud R, Prakash V, Krowarsch D, Langsrud T, Kaul P, Devold TG, Vegarud GE. A comparison of effects of pH on the thermal stability and conformation of caprine and bovine lactoferrin. Int Dairy J. 2010;20:487-94.
14. Shimazaki KI, Tanaka T, Kon H, Oota K, Kawaguchi A, Maki Y, Sato T, Ueda Y, Tomimura T, Shimamura S. Separation and characterization of the C-terminal half molecule of bovine lactoferrin. J Dairy Sci. 1993;76:946-55.
15. Bai X, Teng D, Tian Z, Zhu Y, Yang Y, Wang J. Contribution of bovine lactoferrin inter-lobe region to iron binding stability and antimicrobial activity against Staphylococcus aureus. Biometals. 2010;23:431-9.
16. Steijns JM, Van Hooijdonk A. Occurrence, structure, biochemical properties and technological characteristics of lactoferrin. Br J Nutr. 2000;84:11-7.
17. Grossmann JG, Neu M, Pantos E, Schwab FJ, Evans RW, Townes-Andrews E, Lindley PF, Appel H, Thies WG, Hasnain SS. X-ray solution scattering reveals conformational changes upon iron uptake in lactoferrin, serum and ovo-transferrins. J Mol Biol. 1992;225:811-9.
18. Andersen BF, Baker HM, Morris GE, Rumball SV, Baker EN. Apolactoferrin structure demonstrates ligand-induced conformational change in transferrins. Nature. 1990;344:784-7.
19. Gerstein M, Anderson BF, Norris GE, Baker EN, Lesk AM, Chothia C. Domain closure in lactoferrin: Two hinges produce a see-saw motion between alternative close-packed interfaces. J Mol Biol. 1993;234:357-72.
20. Jameson G. B.; Anderson B. F.; Norris G. E.; Thomas D.; Baker E., Structure of human apolactoferrin at 2.0 A resolution. Refinement and analysis of ligand-induced conformational change. Acta Crystallogr D Biol Crystallogr. 1998;54:1319-35.
21. Haridas M, Anderson B, Baker E. Structure of human diferric lactoferrin refined at 2.2 A resolution. Acta Crystallogr D Biol Crystallogr. 1995;51:629-46.
22. Moore SA, Anderson BF, Groom CR, Haridas M, Baker EN. Three-dimensional structure of diferric bovine lactoferrin at 2.8 Å resolution. J Mol Biol. 1997; 274:222-36.
23. Van Berkel P, Geerts ME, Van Veen HA, Kooiman PM, Pieper FR, De Boer HA, Nuijens JH. Glycosylated and unglycosylated human lactoferrins both bind iron and show identical affinities towards human lysozyme and bacterial lipopolysaccharide, but differ in their susceptibilities towards tryptic proteolysis. Biochem J. 1995;312:107-14.
24. Wei Z, Nishimura T, Yoshida S. Characterization of glycans in a lactoferrin isoform, lactoferrin-a. J Dairy Sci. 2001;84:2584-90.
25. Baker E, Baker H. Molecular structure, binding properties and dynamics of lactoferrin. Cell Mol Life Sci. 2005;62:2531-9.
26. Patel HA, Singh H, Anema SG, Creamer LK. Effects of heat and high hydrostatic pressure treatments on disulfide bonding interchanges among the proteins in skim milk. J Agric Food Chem. 2006;54:3409-20.
27. Brock JH. Lactoferrin structure-function relationships. Totowa: Humana Press; 1997. p. 3-23.
28. Khan JA, Kumar P, Paramasivam M, Yadav RS, Sahani MS, Sharma S, Srinivasan A, Singh TP. Camel lactoferrin, a transferrin-cum-lactoferrin: crystal structure of camel apolactoferrin at 2.6 Å resolution and structural basis of its dual role. J Mol Biol. 2001;309:751-61.
29. Rüegg M, Moor U, Blanc B. A calorimetric study of the thermal denaturation of whey proteins in simulated milk ultrafiltrate. J Dairy Res. 1977;44:509-20.
30. Abe H, Saito H, Miyakawa H, Tamura Y, Shimamura S, Nagao E, Tomita M. Heat stability of bovine lactoferrin at acidic pH. J Dairy Sci. 1991;74:65-71.
31. Paulsson MA, Svensson U, Kishore AR, Satyanarayan NA. Thermal behavior of bovine lactoferrin in water and its relation to bacterial interaction and antibacterial activity. J Dairy Sci. 1993;76:3711-20.
32. Oria R, Ismail M, Sánchez L, Calvo M, Brock JH. Effect of heat treatment and other milk proteins on the interaction of lactoferrin with monocytes. J Dairy Res. 1993;60:363-9.
33. Sánchez L, Peiro J, Castillo H, Perez M, Ena J, Calvo M. Kinetic parameters for denaturation of bovine milk lactoferrin. J Food Sci. 1992;57:873-9.
34. Liu M, Du M, Kong YY, Zhang LW. Purification and Effect of Heat Treatment on Properties of Lactoferrin. J Food Sci Technol. 2013;31:26-30.
35. Kussendrager K. Effects of heat treatment on structure and iron-binding capacity of bovine lactoferrin. Paper presented at: Indigenous Antimicrobial Agents of Milk-Recent Developments 1994; Uppsala, Sweden.
36. Kawakami H, Hiratsuka M, Dosako S. Effects of iron-saturated lactoferrin on iron absorption. Agric Biol Chem. 1988;52:903-8.
37. Hagiwara T, Ozawa K, Fukuwatari Y, Hayasawa H, Hirohata Y, Adachi A, Kanda S, Aihara K. Effects of lactoferrin on iron absorption in immature mice. Nutr Res. 1997;17:895-906.
38. Iyer S, Lonnerdal B. Lactoferrin, lactoferrin receptors and iron metabolism. Eur J Clin Nutr. 1993;47:232-41.
39. Saarinen UM, Siimes MA. Iron absorption from infant milk formula and the optimal level of iron supplementation. Acta Paediatr. 1977;66:719-22.
40. Chierici R, Sawatzki G, Tamisari L, Volpato S, Vigi V. Supplementation of an adapted formula with bovine lactoferrin. 2. Effects on serum iron, ferritin and zinc levels. Acta Paediatr. 1992;81:475-9.
41. King Jr JC, Cummings GE, Guo N, Trivedi L, Readmond BX, Keane V, Feigelman S, Waard RD. A double-blind, placebo-controlled, pilot study of bovine lactoferrin supplementation in bottle-fed infants. J Pediatr Gastroenterol Nutr. 2007;44:245-51.
42. Chen GY, Chen TX, Chen HJ, He ZJ, Wu SM. Effect of lactoferrin fortified formula on infant growth and development and the accounts of peripheral blood cells. Chin J Postgrad Med. 2011;34:52-5.
43. Ke C, Zhang L, Li H, Zhang Y, Xie H, Shang J, Tian WZ, Yang P, Chai LY, Mao M. Iron metabolism in infants: influence of bovine lactoferrin from iron-fortified formula. Nutrition. 2015;31:304-9.
44. Koikawa N, Nagaoka I, Yamaguchi M, Hamano H, Yamauchi K, Sawaki K. Preventive effect of lactoferrin intake on anemia in female long distance runners. Biosci Biotechnol Biochem. 2008;72:931-5.
45. Paesano R, Torcia F, Berlutti F, Pacifici E, Ebano V, Moscarini M, Valenti P. Oral administration of lactoferrin increases hemoglobin and total serum iron in pregnant women. Biochem Cell Biol. 2006;84:377-80.
46. Paesano R, Pietropaoli M, Gessani S, Valenti P. The influence of lactoferrin, orally administered, on systemic iron homeostasis in pregnant women suffering of iron deficiency and iron deficiency anaemia. Biochimie. 2009;91:44-51.
47. Paesano R, Berlutti F, Pietropaoli M, Goolsbee W, Pacifici E, Valenti P. Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women. Int J Immunopathol Pharmacol. 2010;23:577-87.
48. Wang X, Liu S, Xu H, Yan W. Effects of recombinant human lactoferrin on improving the iron status of IDA rats. J Hyg Res. 2012;41: 13-17.
49. Davidsson L, Kastenmayer P, Yuen M, Lönnerdal B, Hurrell RF. Influence of lactoferrin on iron absorption from human milk in infants. Pediatr Res. 1994;35:117-24.
50. Hernell O, Lönnerdal B. Iron status of infants fed low-iron formula: no effect of added bovine lactoferrin or nucleotides. Am J Clin Nutr. 2002;76:858-64.
51. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta. 1992;1121:130-6.
52. Sherman MP, Bennett SH, Hwang FF, Yu C. Neonatal small bowel epithelia: enhancing anti-bacterial defense with lactoferrin and Lactobacillus GG. Biometals. 2004;17:285-9.
53. Håversen L, Kondori N, Baltzer L, Hanson L, Dolphin G, Duner K, Mattsby-Baltzer I. Structure-microbicidal activity relationship of synthetic fragments derived from the antibacterial a-helix of human lactoferrin. Antimicrob Agents Chemother. 2010;54:418-25.
54. Hara K, Ikeda M, Saito S, Matsumoto S, Numata K, Kato N, Tanaka K, Sekihara H. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res. 2002;24:228-35.
55. Qiu J, Hendrixson DR, Baker EN, Murphy TF, Geme JWS, Plaut AG. Human milk lactoferrin inactivates two putative colonization factors expressed by Haemophilus influenzae. Proc Natl Acad Sci. 1998;95:12641-6.
56. Arnold R, Russell J, Champion W, Gauthier J. Bactericidal activity of human lactoferrin: influence of physical conditions and metabolic state of the target microorganism. Infect Immun. 1981;32:655-60.
57. Reyes R, Manjarrez H, Drago M. El hierro and la virulencia bacteriana. Enf Inf Microbiol. 2005;25:104-7.
58. Leitch E, Willcox M. Elucidation of the antistaphylococcal action of lactoferrin and lysozyme. J Med Microbiol. 1999;48:867-71.
59. Coughlin RT, Tonsager S, McGroarty EJ. Quantitation of metal cations bound to membranes and extracted lipopolysaccharide of Escherichia coli. Biochemistry. 1983;22:2002-7.
60. Roseanu A, Florian P, Condei M, Cristea D, Damian M. Antibacterial activity of Lactoferrin and Lactoferricin against oral Streptococci. Rom Biotechnol Lett. 2010;15:5789-92.
61. Wakabayashi H, Kondo I, Kobayashi T, Yamauchi K, Toida T, Iwatsuki K, Yoshie H. Periodontitis, periodontopathic bacteria and lactoferrin. Biometals. 2010;23:419-24.
62. Van der Strate B, Beljaars L, Molema G, Harmsen M, Meijer D. Antiviral activities of lactoferrin. Antiviral Res. 2001;52:225-39.
63. Andersen JH, Jenssen H, Sandvik K, Gutteberg TJ. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J Med Virol. 2004;74:262-71.
64. Hasegawa K, Motsuchi W, Tanaka S, Dosako S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn J Med Sci Biol. 1994;47:73-85.
65. Marr AK, Jenssen H, Moniri MR, Hancock R, Panté N. Bovine lactoferrin and lactoferricin interfere with intracellular trafficking of Herpes simplex virus-1. Biochimie. 2009;91:160-4.
66. Viani RM, Gutteberg TJ, Lathey JL, Spector SA. Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine. AIDS. 1999;13:1273-4.
67. Beljaars L, van der Strate BW, Bakker HI, Reker-Smit C, van Loenen-Weemaes A-M, Wiegmans FC, Harmsen MC, Molema G, Meijer DK. Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. Antiviral Res. 2004;63:197-208.
68. Andersen JH, Osbakk SA, Vorland LH, Traavik T, Gutteberg TJ. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res. 2001;51:141-9.
69. Ikeda M, Nozaki A, Sugiyama K, Tanaka T, Naganuma A, Tanaka K, Sekihara H, Shimotohno K, Saito M, Kato N. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res. 2000;66:51-63.
70. Ikeda M, Sugiyama K, Tanaka T, Tanaka K, Sekihara H, Shimotohno K, Kato N. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun. 1998;245:549-53.
71. Sato R, Inanami O, Tanaka Y, Takase M, Naito Y. Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus (FIV)-positive and FIV-negative cats. Am J Vet Res. 1996;57:1443-6.
72. Beaumont SL, Maggs DJ, Clarke HE. Effects of bovine lactoferrin on in vitro replication of feline herpesvirus. Vet Ophthalmol. 2003;6:245-50.
73. Seganti L, Di Biase AM, Marchetti M, Pietrantoni A, Tinari A, Superti F. Antiviral activity of lactoferrin towards naked viruses. Biometals. 2004;17:295-9.
74. Arnold R, Brewer M, Gauthier J. Bactericidal activity of human lactoferrin: sensitivity of a variety of microorganisms. Infect Immun. 1980;28:893-8.
75. Bellamy W, Wakabayashi H, Takase M, Kawase K, Shimamura S, Tomita M. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med Microbiol Immunol. 1993;182:97-105.
76. Wakabayashi H, Abe S, Okutomi T, Tansho S, Kawase K, Yamaguchi H. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol Immunol. 1996;40:821-5.
77. Kuipers M, De Vries H, Eikelboom M, Meijer D, Swart P. Synergistic Fungistatic Effects of Lactoferrin in Combination with Antifungal Drugs against ClinicalCandida Isolates. Antimicrob Agents Chemother. 1999;43:2635-41.
78. Kondori N, Baltzer L, Dolphin G, Mattsby-Baltzer I. Fungicidal activity of human lactoferrin-derived peptides based on the antimicrobial aβ region. Int J Antimicrob Agents. 2011;37:51-7.
79. Valenti P, Visca P, Antonini G, Orsi N. Interaction between lactoferrin and ovotransferrin and Candida cells. FEMS Microbiol Lett. 1986;33:271-5.
80. Xu Y, Samaranayake Y, Samaranayake L, Nikawa H. In vitro susceptibility of Candida species to lactoferrin. Med Mycol. 1999;37:35-41.
81. Nikawa H, Samaranayake L, Hamada T. Modulation of the anti-candida activity of apo-lactoferrin by dietary sucrose and tunicamycin in vitro. Arch Oral Biol. 1995;40:581-4.
82. Nikawa H, Samaranayake L, Tenovuo J, Pang K, Hamada T. The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei. Arch Oral Biol. 1993;38:1057-63.
83. Zarember KA, Sugui JA, Chang YC, Kwon-Chung KJ, Gallin JI. Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion. J Immunol. 2007;178:6367-73.
84. Lupetti A, Van Dissel J, Brouwer C, Nibbering P. Human antimicrobial peptides' antifungal activity against Aspergillus fumigatus. Eur J Clin Microbiol Infect Dis. 2008;27:1125-9.
85. Van der Kraan MI, Groenink J, Nazmi K, Veerman EC, Bolscher JG, Nieuw Amerongen AV. Lactoferrampin: a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides. 2004;25:177-83.
86. Wakabayashi H, Uchida K, Yamauchi K, Teraguchi S, Hayasawa H, Yamaguchi H. Lactoferrin given in food facilitates dermatophytosis cure in guinea pig models. J Antimicrob Chemother. 2000;46:595-602.
87. Viejo-Díaz M, Andrés MT, Fierro JF. Modulation of in vitro fungicidal activity of human lactoferrin against Candida albicans by extracellular cation concentration and target cell metabolic activity. Antimicrob Agents Chemother. 2004;48:1242-8.
88. Kuwata H, Yip T-T, Tomita M, Hutchens TW. Direct evidence of the generation in human stomach of an antimicrobial peptide domain (lactoferricin) from ingested lactoferrin. Biochim Biophys Acta. 1998;1429:129-41.
89. Dionysius D, Milne J. Antibacterial peptides of bovine lactoferrin: purification and characterization. J Dairy Sci. 1997;80:667-74.
90. Vogel HJ, Schibli DJ, Jing W, Lohmeier-Vogel EM, Epand RF, Epand RM. Towards a structure-function analysis of bovine lactoferricin and related tryptophan-and arginine-containing peptides. Biochem Cell Biol. 2002;80:49-63.
91. Yamauchi K, Tomita M, Giehl T, Ellison R. r., Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun. 1993;61:719-28.
92. Wakabayashi H, Matsumoto H, Hashimoto K, Teraguchi S, Takase M, Hayasawa H. N-Acylated and D enantiomer derivatives of a nonamer core peptide of lactoferricin B showing improved antimicrobial activity. Antimicrob Agents Chemother. 1999;43:1267-9.
93. Wakabayashi H, Hiratani T, Uchida K, Yamaguchi H. Antifungal spectrum and fungicidal mechanism of an N-terminal peptide of bovine lactoferrin. J Infect Chemother. 1996;1:185-9.
94. Valenti P, Antonini G, Siciliano R, Rega B, Superti F, Marchetti M, Ammendolia M, Seganti L, Shimazaki K, Tsuda H. Antiviral activity of lactoferrin-derived peptides. Paper presented at: Lactoferrin: structure, function and applications. Proceedings of the 4th International Conference on Lactoferrin: Structure, Function and Applications, held in Sapporo, Japan 18-22 May 1999. 2000.
95. Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki KI, Azuma I. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Cancer Sci. 1997;88:184-90.
96. Iigo M, Kuhara T, Ushida Y, Sekine K, Moore MA, Tsuda H. Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. Clin Exp Metastasis. 1999;17:43-9.
97. Kuwata H, Yip T-T, Yip CL, Tomita M, Hutchens TW. Bactericidal domain of lactoferrin: detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry. Biochem Biophys Res Commun. 1998;245:764-73.
98. Rekdal Ø, Andersen J, Vorland LH, Svendsen JS. Construction and synthesis of lactoferricin derivatives with enhanced antibacterial activity. J Pept Sci. 1999;5:32-45.
99. Strøm MB, Svendsen JS, Rekdal Ø. Antibacterial activity of 15-residue lactoferricin derivatives. J Pept Res. 2000;56:265-74.
100. Kang JH, Lee MK, Kim KL, Hahm KS. Structure-biological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin. Int J Pept Protein Res. 1996;48:357-63.
101. Tomita M, Takase M, Bellamy W, Shimamura S. A review: the active peptide of lactoferrin. Pediatr Int. 1994;36:585-91.
102. Yoshimaki T, Sato S, Tsunori K, Shino H, Iguchi S, Arai Y, Ito K, Ogiso B. Bone regeneration with systemic administration of lactoferrin in non-critical-sized rat calvarial bone defects. J Oral Sci. 2013;55:343-8.
103. Malet A, Bournaud E, Lan A, Mikogami T, Tomé D, Blais A. Bovine lactoferrin improves bone status of ovariectomized mice via immune function modulation. Bone. 2011;48:1028-35.
104. Melton LJ, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res. 1997;12:1083-91.
105. Grey A, Banovic T, Zhu Q, Watson M, Callon K, Palmano K, Ross J, Naot D, Reid IR, Cornish J. The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol. 2004;18:2268-78.
106. Grey A, Zhu Q, Watson M, Callon K, Cornish J. Lactoferrin potently inhibits osteoblast apoptosis, via an LRP1-independent pathway. Mol Cell Endocrinol. 2006;251:96-102.
107. Lorget F, Clough J, Oliveira M, Daury M-C, Sabokbar A, Offord E. Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. Biochem Biophys Res Commun. 2002;296:261-6.
108. Takayama Y, Mizumachi K. Effect of lactoferrin-embedded collagen membrane on osteogenic differentiation of human osteoblast-like cells. J Biosci Bioeng. 2009;107:191-5.
109. Hou JM, Xue Y, Lin QM. Bovine lactoferrin improves bone mass and microstructure in ovariectomized rats via OPG/RANKL/RANK pathway. Acta Pharmacol Sin. 2012;33:1277-84.
110. Wang X, Guo H, Zhang W, Wen PC, Zhang H, Ren FZ. Effect of iron saturation level of lactoferrin on osteogenic activity in vitro and in vivo. J Dairy Sci. 2013;96:33-9.
111. Cornish J, Naot D. Lactoferrin as an effector molecule in the skeleton. Biometals. 2010;23:425-30.
112. Nishimoto S, Nishida E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep. 2006;7:782-6.
113. Raucci A, Bellosta P, Grassi R, Basilico C, Mansukhani A. Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways. J Cell Physiol. 2008;215:442-51.
114. Stanton LA, Beier F. Inhibition of p38 MAPK signaling in chondrocyte cultures results in enhanced osteogenic differentiation of perichondral cells. Exp Cell Res. 2007;313:146-55.
115. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37-40.
116. Hipskind RA, Bilbe G. MAP kinase signaling cascades and gene expression in osteoblasts. Front Biosci. 1998;3:d804-16.
117. Wang X, Goh CH, Li B. p38 mitogen-activated protein kinase regulates osteoblast differentiation through osterix. Endocrinology. 1629-1637;2007:148.
118. Ge C, Xiao G, Jiang D, Franceschi RT. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J Cell Biol. 2007;176:709-18.
119. Wright T, Goodman S. Implant wear in total joint replacement: clinical and biologic issues, material and design considerations: Symposium. Oakbrook: American Academy of Orthopaedic Surgeons; 2001.
120. Archibeck MJ, Jacobs JJ, Roebuck KA, Glant TT. The basic science of periprosthetic osteolysis. J Bone Joint Surg. 2000;82:1478-8.
121. Li X, Udagawa N, Takami M, Sato N, Kobayashi Y, Takahashi N. p38 Mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production, phagocytosis, or dendritic cell differentiation of bone marrow macrophages. Endocrinology. 2003;144:4999-5005.
122. Mulder AM, Connellan PA, Oliver CJ, Morris CA, Stevenson LM. Bovine lactoferrin supplementation supports immune and antioxidant status in healthy human males. Nutr Res. 2008;28:583-9.
123. Hwang SA, Kruzel ML, Actor JK. Immunomodulatory effects of recombinant lactoferrin during MRSA infection. I. 2014;20:157-63.
124. Legrand D, Mazurier J. A critical review of the roles of host lactoferrin in immunity. Biometals. 2010;23:365-76.
125. Legrand D, Elass E, Pierce A, Mazurier J. Lactoferrin and host defence: an overview of its immuno-modulating and anti-inflammatory properties. Biometals. 2004;17:225-9.
126. Ward PP, Mendoza-Meneses M, Park PW, Conneely OM. Stimulus-dependent impairment of the neutrophil oxidative burst response in lactoferrin-deficient mice. Am J Pathol. 2008;172:1019-29.
127. Legrand D, Elass E, Carpentier M, Mazurier J. Interactions of lactoferrin with cells involved in immune function. Biochem Cell Biol. 2006;84:282-90.
128. Legrand D, Elass E, Carpentier M, Mazurier J. Lactoferrin. Cell Mol Life Sci. 2005;62:2549-59.
129. Wakabayashi H, Takase M, Tomita M. Lactoferricin derived from milk protein lactoferrin. Curr Pharm Des. 2003;9:1277-87.
130. Kanyshkova T, Buneva V, Nevinsky G. Lactoferrin and its biological functions. Biochemistry (Mosc). 2001;66:1-7.
131. Rodrigues L, Teixeira J, Schmitt F, Paulsson M, Månsson HL. Lactoferrin and cancer disease prevention. Crit Rev Food Sci Nutr. 2008;49:203-17.
132. Tuccari G, Barresi G. Lactoferrin in human tumours: immunohistochemical investigations during more than 25 years. Biometals. 2011;24:775-84.
133. McKeown ST, Lundy FT, Nelson J, Lockhart D, Irwin CR, Cowan CG, Marley JJ. The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. Oral Oncol. 2006;42:685-90.
134. Yang N, Strøm MB, Mekonnen SM, Svendsen JS, Rekdal Ø. The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. J Pept Sci. 2004;10:37-46.
135. Duarte D, Nicolau A, Teixeira J, Rodrigues L. The effect of bovine milk lactoferrin on human breast cancer cell lines. J Dairy Sci. 2011;94:66-76.
136. Tsuda H, Kozu T, Iinuma G, Ohashi Y, Saito Y, Saito D, Akasu T, Alexander DB, Futakuchi M, Fukamachi K. Cancer prevention by bovine lactoferrin: from animal studies to human trial. Biometals. 2010;23:399-409.
137. Wolf JS, Li G, Varadhachary A, Petrak K, Schneyer M, Li D, Ongkasuwan J, Zhang X, Taylor RJ, Strome SE. Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo. Clin Cancer Res. 2007;13:1601-10.
138. Varadhachary A, Wolf JS, Petrak K, O'Malley BW, Spadaro M, Curcio C, Forni G, Pericle F. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer. 2004;111:398-403.
139. Xiao Y, Monitto CL, Minhas KM, Sidransky D. Lactoferrin down-regulates G1 cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin Cancer Res. 2004;10:8683-6.
140. Damiens E, El Yazidi I, Mazurier J, Duthille I, Spik G, Boilly-Marer Y. Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J Cell Biochem. 1999;74:486-98.
141. Kuhara T, Iigo M, Itoh T, Ushida Y, Sekine K, Terada N, Okamura H, Tsuda H. Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer. 2000;38:192-9.
142. Wang WP, Iigo M, Sato J, Sekine K, Adachi I, Tsuda H. Activation of Intestinal Mucosal Immunity in Tumor-bearing Mice by Lactoferrin. Cancer Sci. 2000;91:1022-7.
143. Ming YC, Ho WJ, Xia J, Bun NT. Studies on anticancer activities of lactoferrin and lactoferricin. Curr Protein Pept Sci. 2013;14:492-503.
144. Sakai T, Banno Y, Kato Y, Nozawa Y, Kawaguchi M. Pepsin-digested bovine lactoferrin induces apoptotic cell death with JNK/SAPK activation in oral cancer cells. J Pharmacol Sci. 2005;98:41-8.
145. Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH, Rekdal Ø. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res. 2002;22:2703-10.
146. Yang N, Rekdal Ø, Stensen W, Svendsen J. Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. J Pept Res. 2002;60:187-97.
147. Ma J, Guan R, Shen H, Lu F, Xiao C, Liu M, Kang T. Comparison of anticancer activity between lactoferrin nanoliposome and lactoferrin in Caco-2 cells in vitro. Food Chem Toxicol. 2013;59:72-7.
148. Lindmark-Månsson H, Åkesson B. Antioxidative factors in milk. Br J Nutr. 2000;84:103-10.
149. Baker HM, Anderson BF, Baker EN. Dealing with iron: common structural principles in proteins that transport iron and heme. Proc Natl Acad Sci. 2003;100:3579-83.
150. Satué-Gracia MT, Frankel EN, Rangavajhyala N, German JB. Lactoferrin in infant formulas: effect on oxidation. J Agric Food Chem. 2000;48:4984-90.
151. Wang Y, Xu C, An Z, Liu J, Feng J. Effect of dietary bovine lactoferrin on performance and antioxidant status of piglets. Anim Feed Sci Technol. 2008;140:326-36.
152. Maneva A, Taleva B, Maneva L. Lactoferrin-protector against oxidative stress and regulator of glycolysis in human erythrocytes. Z Naturforsch C. 2003;58:256-62.
153. Safaeian L, Zabolian H. Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat. ISRN Pharmacol. 2014;2014:943523-9.
154. Kanyshkova TYG, Babina SE, Semenov DV, Isaeva NY, Vlassov AV, Neustroev KN, Kul'minskaya AA, Buneva VN, Nevinsky GA. Multiple enzymic activities of human milk lactoferrin. Eur J Biochem. 2003;270:3353-61.
155. öztafl YE, özgünefl N. Lactoferrin: a multifunctional protein. Adv Mol Med. 2005;1:149-54.
156. Semenov DV, Kanyshkova TG, Buneva VN, Nevinsky GA. Human milk lactoferrin binds ATP and dissociates into monomers. IUBMB Life. 1999;47:177-84.
157. Kanyshkova TYG, Semenov DV, Buneva VN, Nevinsky GA. Human milk lactoferrin binds two DNA molecules with different affinities. FEBS Lett. 1999;451:235-7.
158. Furmanski P, Li Z, Fortuna MB, Swamy C, Das MR. Multiple molecular forms of human lactoferrin. Identification of a class of lactoferrins that possess ribonuclease activity and lack iron-binding capacity. J Exp Med. 1989;170:415-29.
159. Ono T, Morishita S, Murakoshi M. Novel function of bovine lactoferrin in lipid metabolism: visceral fat reduction by enteric-coated lactoferrin. Pharma Nutrition. 2013;1:32-4.
160. Ono T, Murakoshi M, Suzuki N, Iida N, Ohdera M, Iigo M, Yoshida T, Sugiyama K, Nishino H. Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. Br J Nutr. 1688-1695;2010:104.
161. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, Jiang X. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. J Control Release. 2009;134:55-61.
162. Hu K, Shi Y, Jiang W, Han J, Huang S, Jiang X. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease. Int J Pharm. 2011;415:273-83.
163. Yu Y, Pang Z, Lu W, Yin Q, Gao H, Jiang X. Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery. Pharm Res. 2012;29:83-96.
164. Huang R, Ke W, Liu Y, Wu DD, Feng LY, Jiang C, Pei YY. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci. 2010;290:123-30.